We develop genetic medicines for people living with rare and ultrarare diseases — conditions that have been waiting for the science to catch up. It has. We're building.
Get in touch →This may be the last generation where patients with rare diseases have no real options. In the past two decades, progress has been building up in every component of the complex chain that makes a medicine - effector chemistry, delivery vehicles, target biology, preclinical models, manufacturing solutions, regulatory innovation.
We started Stitch because the time is right. In many cases, we can assemble these tools into a medicine. Antisense chemistry has a clear regulatory path. Muscle delivery has real options. And computational tools can now accelerate the design work that once took years. The patients who have been waiting the longest — children with rare exon deletions in DMD, conditions too small for traditional pipelines — can finally be reached.
We are scientists and engineers. But we are also parents, siblings, and friends. We know the names behind the diagnoses we work on.
We design antisense oligonucleotides — short, precise sequences that redirect the cellular machinery to skip, silence, or correct broken genetic instructions. Decades of chemistry, refined for the smallest patient populations.
Duchenne Muscular Dystrophy affects many exons — but approved therapies cover only the most common deletions. Children with rare exon deletions have had no options. We are building therapies for exactly those patients, starting now.
Delivery has always been the bottleneck. We leverage emerging delivery platforms to cut time-to-patient, but we also engineer fit-for-purpose shuttles conjugates on the back of proven mechanisms.
DMD is where we start, not where we stop. Computational design tools now let a small, expert team move across conditions that once required entire discovery organizations. We intend to build medicines for patients who have never had a program designed for them.
The rare disease community has fought hard and won important battles. But for every approved therapy, there are dozens of mutations, thousands of patients, and entire disease subtypes that remain without treatment.
Genetic medicine is uniquely positioned to close this gap — and we intend to use it.
We are a small team with deep conviction. We move with urgency because the patients we work for don't have the luxury of time.
Our science is built on deep mechanistic understanding. We don't cut corners on the biology because we can't afford to be wrong.
We work closely with patients and families. They are not endpoints. They are the reason every experiment gets done.
Children with DMD are losing muscle while timelines slip. We build urgency into every decision, every hire, every experiment.
Let's talk
Whether you're a scientist, a potential partner, an investor, or a family affected by rare disease — we want to hear from you.